The dry powder inhaler market size has grown steadily in recent years. It will grow from $22.18 billion in 2025 to $23.25 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing prevalence of asthma and COPD, widespread use of inhalation therapy, improvements in dry powder formulation technologies, expansion of home-based respiratory care, availability of affordable inhaler devices.
The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $28.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing integration of smart inhaler technologies, rising focus on personalized respiratory care, expansion of remote patient monitoring, growing demand for environmentally friendly inhalers, increasing adoption of digital health ecosystems. Major trends in the forecast period include increasing adoption of digitally operated inhalers, rising demand for patient-adherence monitoring, growing focus on portable and user-friendly designs, expansion of multi-dose inhaler platforms, enhanced focus on dose accuracy.
The increasing prevalence of respiratory diseases is anticipated to boost the growth of the dry powder inhaler market in the future. Respiratory diseases encompass a wide range of disorders affecting the respiratory system, including various lung diseases. Dry powder inhalers play a critical role in treating respiratory conditions such as asthma, COPD, and cystic fibrosis by delivering medication directly to the lungs, where it is most effective. This method serves as a promising alternative to traditional drug delivery techniques for respiratory issues. For example, a study published in December 2023 by JAMA Network Open, a medical journal of the American Medical Association, indicates that the global burden of chronic obstructive pulmonary disease (COPD) is projected to nearly reach 600 million cases worldwide by 2050, reflecting a 23% increase in prevalence. Notably, cases among females are expected to surge by 47.1%, while male cases are projected to rise by only 9.4%. Additionally, the majority of these cases are expected to occur in low- and middle-income regions, where the prevalence is anticipated to be more than double that of high-income areas by 2050. Consequently, the growing prevalence of respiratory diseases will significantly drive the expansion of the dry powder inhaler market.
Key players in the dry powder inhaler market are focusing on developing innovative products featuring muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD) while also expanding their product portfolios. Muscarinic antagonists are drugs that inhibit the muscarinic acetylcholine receptor, and they are used to manage various conditions, including COPD and organophosphate poisoning. For example, in March 2024, Berry Global, a US-based company recognized for its development and manufacturing of diverse flexible packaging solutions, unveiled its new dry powder inhaler at Pharma Pack. This inhaler is specifically designed to improve drug delivery for respiratory conditions such as COPD and asthma, providing a customizable solution for pharmaceutical companies.
In August 2024, Aptar Pharma, a US-based specialist in drug delivery, acquired the Orbital Dry Powder Inhaler for an undisclosed sum. This acquisition strengthens Aptar's capabilities in respiratory drug delivery, especially for managing conditions such as asthma and chronic obstructive pulmonary disease (COPD). The Orbital Dry Powder Inhaler is noted for its innovative design, which enhances medication delivery. This acquisition aligns with Aptar Pharma's strategy to expand its product offerings and reinforce its position in the respiratory treatment market. The Orbital DPI operates within the pharmaceutical and medical device sectors in India.
Major companies operating in the dry powder inhaler market are Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, Hovione, MannKind Corporation, Presspart Manufacturing Ltd, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.
North America was the largest region in the dry powder inhaler market in 2025. The regions covered in the dry powder inhaler market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dry powder inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the dry powder inhaler market by increasing costs of imported plastics, precision molds, electronic sensors, drug formulation equipment, and packaging materials. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported components, while Asia-Pacific faces production cost pressures for export markets. These tariffs are increasing device and drug-delivery system costs. However, they are also encouraging local manufacturing, regional sourcing of components, and innovation in cost-efficient and sustainable inhaler designs.
The dry powder inhaler market research report is one of a series of new reports that provides dry powder inhaler market statistics, including dry powder inhaler industry global market size, regional shares, competitors with a dry powder inhaler market share, detailed dry powder inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the dry powder inhaler industry. This dry powder inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A dry powder inhaler (DPI) is a medical device designed for delivering medication in the form of dry powder directly to the lungs. It is primarily used for treating respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). To effectively use a DPI, it is crucial for the user to inhale rapidly and deeply, allowing the medication to reach the lungs.
The main types of dry powder inhalers include single-dose inhalers and multi-dose inhalers. Single-dose inhalers are devices that administer medication directly to the lungs in the form of dry powder. These devices can be either manually operated or digitally operated, and they find applications in treating conditions such as asthma, COPD, cystic fibrosis, and others. Various end-users, including hospitals and clinics, homecare settings, and ambulatory surgical centers, utilize these inhalers.
The dry powder inhaler market consists of sales of dry powder forms, spiriva handihalers, breath-activated inhalers, rotahalers, diskus devices, and twisthaler inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $28.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing integration of smart inhaler technologies, rising focus on personalized respiratory care, expansion of remote patient monitoring, growing demand for environmentally friendly inhalers, increasing adoption of digital health ecosystems. Major trends in the forecast period include increasing adoption of digitally operated inhalers, rising demand for patient-adherence monitoring, growing focus on portable and user-friendly designs, expansion of multi-dose inhaler platforms, enhanced focus on dose accuracy.
The increasing prevalence of respiratory diseases is anticipated to boost the growth of the dry powder inhaler market in the future. Respiratory diseases encompass a wide range of disorders affecting the respiratory system, including various lung diseases. Dry powder inhalers play a critical role in treating respiratory conditions such as asthma, COPD, and cystic fibrosis by delivering medication directly to the lungs, where it is most effective. This method serves as a promising alternative to traditional drug delivery techniques for respiratory issues. For example, a study published in December 2023 by JAMA Network Open, a medical journal of the American Medical Association, indicates that the global burden of chronic obstructive pulmonary disease (COPD) is projected to nearly reach 600 million cases worldwide by 2050, reflecting a 23% increase in prevalence. Notably, cases among females are expected to surge by 47.1%, while male cases are projected to rise by only 9.4%. Additionally, the majority of these cases are expected to occur in low- and middle-income regions, where the prevalence is anticipated to be more than double that of high-income areas by 2050. Consequently, the growing prevalence of respiratory diseases will significantly drive the expansion of the dry powder inhaler market.
Key players in the dry powder inhaler market are focusing on developing innovative products featuring muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD) while also expanding their product portfolios. Muscarinic antagonists are drugs that inhibit the muscarinic acetylcholine receptor, and they are used to manage various conditions, including COPD and organophosphate poisoning. For example, in March 2024, Berry Global, a US-based company recognized for its development and manufacturing of diverse flexible packaging solutions, unveiled its new dry powder inhaler at Pharma Pack. This inhaler is specifically designed to improve drug delivery for respiratory conditions such as COPD and asthma, providing a customizable solution for pharmaceutical companies.
In August 2024, Aptar Pharma, a US-based specialist in drug delivery, acquired the Orbital Dry Powder Inhaler for an undisclosed sum. This acquisition strengthens Aptar's capabilities in respiratory drug delivery, especially for managing conditions such as asthma and chronic obstructive pulmonary disease (COPD). The Orbital Dry Powder Inhaler is noted for its innovative design, which enhances medication delivery. This acquisition aligns with Aptar Pharma's strategy to expand its product offerings and reinforce its position in the respiratory treatment market. The Orbital DPI operates within the pharmaceutical and medical device sectors in India.
Major companies operating in the dry powder inhaler market are Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, Hovione, MannKind Corporation, Presspart Manufacturing Ltd, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.
North America was the largest region in the dry powder inhaler market in 2025. The regions covered in the dry powder inhaler market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dry powder inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the dry powder inhaler market by increasing costs of imported plastics, precision molds, electronic sensors, drug formulation equipment, and packaging materials. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported components, while Asia-Pacific faces production cost pressures for export markets. These tariffs are increasing device and drug-delivery system costs. However, they are also encouraging local manufacturing, regional sourcing of components, and innovation in cost-efficient and sustainable inhaler designs.
The dry powder inhaler market research report is one of a series of new reports that provides dry powder inhaler market statistics, including dry powder inhaler industry global market size, regional shares, competitors with a dry powder inhaler market share, detailed dry powder inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the dry powder inhaler industry. This dry powder inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A dry powder inhaler (DPI) is a medical device designed for delivering medication in the form of dry powder directly to the lungs. It is primarily used for treating respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). To effectively use a DPI, it is crucial for the user to inhale rapidly and deeply, allowing the medication to reach the lungs.
The main types of dry powder inhalers include single-dose inhalers and multi-dose inhalers. Single-dose inhalers are devices that administer medication directly to the lungs in the form of dry powder. These devices can be either manually operated or digitally operated, and they find applications in treating conditions such as asthma, COPD, cystic fibrosis, and others. Various end-users, including hospitals and clinics, homecare settings, and ambulatory surgical centers, utilize these inhalers.
The dry powder inhaler market consists of sales of dry powder forms, spiriva handihalers, breath-activated inhalers, rotahalers, diskus devices, and twisthaler inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Dry Powder Inhaler Market Characteristics
3. Dry Powder Inhaler Market Supply Chain Analysis
4. Global Dry Powder Inhaler Market Trends and Strategies
5. Dry Powder Inhaler Market Analysis of End Use Industries
7. Global Dry Powder Inhaler Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Dry Powder Inhaler Total Addressable Market (TAM) Analysis for the Market
9. Dry Powder Inhaler Market Segmentation
10. Dry Powder Inhaler Market Regional and Country Analysis
11. Asia-Pacific Dry Powder Inhaler Market
12. China Dry Powder Inhaler Market
13. India Dry Powder Inhaler Market
14. Japan Dry Powder Inhaler Market
15. Australia Dry Powder Inhaler Market
16. Indonesia Dry Powder Inhaler Market
17. South Korea Dry Powder Inhaler Market
18. Taiwan Dry Powder Inhaler Market
19. South East Asia Dry Powder Inhaler Market
20. Western Europe Dry Powder Inhaler Market
21. UK Dry Powder Inhaler Market
22. Germany Dry Powder Inhaler Market
23. France Dry Powder Inhaler Market
24. Italy Dry Powder Inhaler Market
25. Spain Dry Powder Inhaler Market
26. Eastern Europe Dry Powder Inhaler Market
27. Russia Dry Powder Inhaler Market
28. North America Dry Powder Inhaler Market
29. USA Dry Powder Inhaler Market
30. Canada Dry Powder Inhaler Market
31. South America Dry Powder Inhaler Market
32. Brazil Dry Powder Inhaler Market
33. Middle East Dry Powder Inhaler Market
34. Africa Dry Powder Inhaler Market
36. Dry Powder Inhaler Market Competitive Landscape and Company Profiles
37. Dry Powder Inhaler Market Other Major and Innovative Companies
40. Dry Powder Inhaler Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Dry Powder Inhaler Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses dry powder inhaler market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dry powder inhaler? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dry powder inhaler market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Single-Dose Inhalers; Multi-Dose Inhalers2) By Function: Manually Operated Inhaler Devices; Digitally Operated Inhaler Devices
3) By Application: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Cystic Fibrosis; Other Applications
4) By End User: Hospitals And Clinics; Homecare Settings; Ambulatory Surgical Centers; Other End Users
Subsegments:
1) By Single-Dose Inhalers: Capsule-Based Inhalers; Diskus-Based Inhalers2) By Multi-Dose Inhalers: Blister-Based Inhalers; Rotahaler-Based Inhalers
Companies Mentioned: Novartis AG; AstraZeneca plc.; GlaxoSmithKline Plc; Boehringer Ingelheim GmbH; Viatris (Mylan N.V); Otsuka Pharmaceutical Co. Ltd; Catalent Inc.; Aptar Group Inc.; Chiesi Farmaceutici S.p.A.; Recipharm AB; Cipla Limited; Lupin Limited; Orion Corporation; Hovione; MannKind Corporation; Presspart Manufacturing Ltd; Teva Pharmaceutical Industries Limited; Pharmaxis Ltd.; Iconovo AB; SRS Pharmaceuticals Pvt. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Dry Powder Inhaler market report include:- Novartis AG
- AstraZeneca plc.
- GlaxoSmithKline Plc
- Boehringer Ingelheim GmbH
- Viatris (Mylan N.V)
- Otsuka Pharmaceutical Co. Ltd
- Catalent Inc.
- Aptar Group Inc.
- Chiesi Farmaceutici S.p.A.
- Recipharm AB
- Cipla Limited
- Lupin Limited
- Orion Corporation
- Hovione
- MannKind Corporation
- Presspart Manufacturing Ltd
- Teva Pharmaceutical Industries Limited
- Pharmaxis Ltd.
- Iconovo AB
- SRS Pharmaceuticals Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 23.25 Billion |
| Forecasted Market Value ( USD | $ 28.16 Billion |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
